XTANDI Shows Long-Term Overall Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

Five-year follow-up data from the Phase 3 ARCHES trial (NCT02677896) demonstrates that XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) s...
Home/KnloSights/Clinical Trial Updates/XTANDI Shows Long-Term Overall Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer